New oral anticoagulants in the treatment of heparin- Induced thrombocytopenia

Mohsen Sharifi, Curt Bay, Zoltan Vajo, Wilbur Freeman, Mirali Sharifi, Frederic Schwartz

Research output: Contribution to journalArticle

26 Citations (Scopus)


Background Heparin induced thrombocytopenia (HIT) is a potentially catastrophic syndrome with a high incidence of vascular thrombosis. There are little data on the efficacy of new oral anticoagulants (NOAC) in this setting. This study reports on the outcome of patients with HIT, treated with NOAC. Materials and Methods We retrospectively identified 22 patients with HIT who were treated by our group with a combination of NOAC and a short course of argatroban. These patients were evaluated in a prospective fashion for development of outcomes at a mean follow up of 19 ± 3 months. Results There were a total of 5 deep and 2 superficial vein thromboses diagnosed at index hospitalization. No patient developed arterial thrombosis. All patients tolerated NOAC and their platelet count normalized before discharge. At 19 months of follow-up, 6 patients had died of non-thrombotic causes. There was no bleeding, limb loss or recurrent venous thromboembolism in any patient. Conclusions In patients with HIT, a short course of parenteral treatment with argatroban followed by administration of a NOAC is highly safe and effective in prevention of thrombosis and normalization of platelet count. Development of HIT however, portends a poor prognosis independent of vascular thrombosis.

Original languageEnglish
Pages (from-to)607-609
Number of pages3
JournalThrombosis research
Issue number4
Publication statusPublished - Apr 1 2015



  • Deep venous thrombosis
  • Heparin- induced thrombocytopenia
  • New oral anticoagulants

ASJC Scopus subject areas

  • Hematology

Cite this